{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T13:18:33Z","timestamp":1776172713425,"version":"3.50.1"},"reference-count":47,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T00:00:00Z","timestamp":1602720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007819","name":"Allergan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007819","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"DOI":"10.3389\/fneur.2020.575130","type":"journal-article","created":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T05:05:01Z","timestamp":1602738301000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["OnabotulinumtoxinA Is an Effective Treatment for Chronic Migraine in Patients With Comorbid Fibromyalgia"],"prefix":"10.3389","volume":"11","author":[{"given":"Mar\u00eda","family":"Sastre Real","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"D\u00edaz de Ter\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2020,10,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e026581","DOI":"10.1136\/bmjopen-2018-026581","article-title":"Bidirectional association between migraine and fibromyalgia: retrospective cohort analyses of two populations","volume":"9","author":"Penn","year":"2019","journal-title":"BMJ Open"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/0333102417738202","article-title":"The international classification of headache disorders, 3rd edition","volume":"38","year":"2018","journal-title":"Cephalalgia"},{"key":"B3","doi-asserted-by":"publisher","first-page":"g1416","DOI":"10.1136\/bmj.g1416","article-title":"Chronic migraine","volume":"348","author":"Schwedt","year":"2014","journal-title":"BMJ"},{"key":"B4","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1007\/978-3-642-86812-2_2","article-title":"The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the Multicenter Criteria Committee","volume":"33","author":"Wolfe","year":"1990","journal-title":"Arthritis Rheum"},{"key":"B5","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1002\/acr.20140","article-title":"The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity","volume":"62","author":"Wolfe","year":"2010","journal-title":"Arthritis Care Res"},{"key":"B6","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1586\/ern.11.190","article-title":"Prevalence, clinical features and potential therapies for fibromyalgia in primary headaches","volume":"12","author":"de Tommaso","year":"2012","journal-title":"Expert Rev Neurother"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1007\/s10067-013-2310-7","article-title":"Fibromyalgia comorbidity in a community sample of adults with migraine","volume":"32","author":"Marcus","year":"2013","journal-title":"Clin Rheumatol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1007\/s10067-013-2218-2","article-title":"The prevalence of fibromyalgia and its relation with headache characteristics in episodic migraine","volume":"32","author":"K\u00fc\u00e7\u00fck\u015fen","year":"2013","journal-title":"Clin Rheumatol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/j.1526-4610.2010.01835.x","article-title":"Migraine and fibromyalgia","volume":"51","author":"Evans","year":"2011","journal-title":"Headache"},{"key":"B10","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1080\/01616412.2019.1630164","article-title":"Comorbid fibromyalgia in migraine patients: clinical significance and impact on daily life","volume":"41","author":"Onder","year":"2019","journal-title":"Neurol Res"},{"key":"B11","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1111\/j.1526-4610.2007.00814.x","article-title":"Migraine comorbidity constellations","volume":"47","author":"Tietjen","year":"2007","journal-title":"Headache"},{"key":"B12","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1111\/j.1468-2982.2005.01060.x","article-title":"Prevalence of fibromyalgia syndrome in migraine patients","volume":"26","author":"Ifergane","year":"2006","journal-title":"Cephalalgia"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1111\/head.13191","article-title":"Fibromyalgia among patients with chronic migraine and chronic tension-type headache: a multicenter prospective cross-sectional study","volume":"57","author":"Cho","year":"2017","journal-title":"Headache"},{"key":"B14","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1111\/j.1468-2982.2008.01754.x","article-title":"Fibromyalgia comorbidity in primary headaches","volume":"29","author":"De Tommaso","year":"2009","journal-title":"Cephalalgia"},{"key":"B15","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s10194-018-0892-9","article-title":"Fibromyalgia in migraine: a retrospective cohort study","volume":"19","author":"Whealy","year":"2018","journal-title":"J Headache Pain"},{"key":"B16","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s10067-005-1121-x","article-title":"Fibromyalgia and headache: an epidemiological study supporting migraine as part of the fibromyalgia syndrome","volume":"24","author":"Marcus","year":"2005","journal-title":"Clin Rheumatol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1111\/j.1526-4610.2009.01521.x","article-title":"Allodynia in migraine: association with comorbid pain conditions","volume":"49","author":"Tietjen","year":"2009","journal-title":"Headache"},{"key":"B18","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/ncprheum0091","article-title":"Mechanisms of disease: pain in fibromyalgia syndrome","volume":"2","author":"Staud","year":"2006","journal-title":"Nat Clin Pract Rheumatol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"A45","DOI":"10.1186\/1129-2377-16-S1-A45","article-title":"Migraine and fibromyalgia","volume":"16","author":"de Tommaso","year":"2015","journal-title":"J Headache Pain"},{"key":"B20","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s10194-017-0764-8","article-title":"Symptoms of central sensitization and comorbidity for juvenile fibromyalgia in childhood migraine: an observational study in a tertiary headache center","volume":"18","author":"de Tommaso","year":"2017","journal-title":"J Headache Pain"},{"key":"B21","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.semarthrit.2018.08.003","article-title":"A systematic review and meta-analysis of the prevalence of small fiber pathology in fibromyalgia: implications for a new paradigm in fibromyalgia etiopathogenesis","volume":"48","author":"Grayston","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1744806918767697","DOI":"10.1177\/1744806918767697","article-title":"Chronic migraine: a process of dysmodulation and sensitization","volume":"14","author":"Su","year":"2018","journal-title":"Mol Pain"},{"key":"B23","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1212\/WNL.0b013e31819749fd","article-title":"Spectrum of illness: understanding biological patterns and relationships in chronic migraine","volume":"72","author":"Aurora","year":"2009","journal-title":"Neurology"},{"key":"B24","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1002\/1531-8249(200005)47:5<614::AID-ANA9>3.0.CO;2-N","article-title":"An association between migraine and cutaneous allodynia","volume":"47","author":"Burstein","year":"2000","journal-title":"Ann Neurol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1177\/0333102410364677","article-title":"OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial","volume":"30","author":"Diener","year":"2010","journal-title":"Cephalalgia"},{"key":"B26","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1177\/0333102410364676","article-title":"OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial","volume":"30","author":"Aurora","year":"2010","journal-title":"Cephalalgia"},{"key":"B27","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/ane.12171","article-title":"OnabotulinumtoxinA for chronic migraine: efficacy, safety, and tolerability in patients who received all five treatment cycles in the PREEMPT clinical program","volume":"129","author":"Aurora","year":"2014","journal-title":"Acta Neurol Scand"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1111\/j.1526-4610.2011.01990.x","article-title":"OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program","volume":"51","author":"Aurora","year":"2011","journal-title":"Headache"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1212\/WNL.0b013e318232ab65","article-title":"OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine","volume":"77","author":"Lipton","year":"2011","journal-title":"Neurology"},{"key":"B30","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s10194-019-0976-1","article-title":"An open-label prospective study of the real-life use of onabotulinumtoxinA for the treatment of chronic migraine: the REPOSE study","volume":"20","author":"Ahmed","year":"2019","journal-title":"J Headache Pain"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1186\/1129-2377-15-54","article-title":"Prospective analysis of the use of onabotulinumtoxinA (BOTOX) in the treatment of chronic migraine; real-life data in (2014) 254 patients from Hull, UK","author":"Khalil","year":"","journal-title":"J Headache Pain"},{"key":"B32","doi-asserted-by":"publisher","first-page":"A137","DOI":"10.1186\/1129-2377-16-S1-A137","article-title":"P070. A 2-year prospective evaluation study on onabotulinumtoxinA 155 U in chronic migraine","volume":"16","author":"Negro","year":"2015","journal-title":"J Headache Pain"},{"key":"B33","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s10194-016-0702-1","article-title":"Real-life data in 115 chronic migraine patients treated with onabotulinumtoxin A during more than one year","volume":"17","author":"Aicua-Rapun","year":"2016","journal-title":"J Headache Pain"},{"key":"B34","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1136\/jnnp-2018-319290","article-title":"Effects of onabotulinumtoxinA treatment for chronic migraine on common comorbidities including depression and anxiety","volume":"90","author":"Blumenfeld","year":"2019","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B35","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s10194-018-0840-8","article-title":"Long-term study of the efficacy and safety of onabotulinumtoxinA for the prevention of chronic migraine: COMPEL study","volume":"19","author":"Blumenfeld","year":"2018","journal-title":"J Headache Pain"},{"key":"B36","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1111\/ene.13523","article-title":"OnabotulinumtoxinA in chronic migraine: predictors of response. A prospective multicentre descriptive study","volume":"25","author":"Dom\u00ednguez","year":"2018","journal-title":"Eur J. Neurol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1177\/0333102414561873","article-title":"Long-term experience with onabotulinumtoxinA in the treatment of chronic migraine: what happens after one year?","volume":"35","author":"Cernuda-Moroll\u00f3n","year":"2015","journal-title":"Cephalalgia"},{"key":"B38","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1186\/s40064-015-0957-z","article-title":"OnabotulinumtoxinA treatment for chronic migraine: experience in 52 patients treated with the PREEMPT paradigm","volume":"4","author":"Pedraza","year":"2015","journal-title":"Springerplus"},{"key":"B39","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s00702-016-1539-0","article-title":"Long-term treatment of chronic migraine with onabotulinumtoxinA: efficacy, quality of life and tolerability in a real-life setting","volume":"123","author":"Kollewe","year":"2016","journal-title":"J Neural Transm"},{"key":"B40","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.clineuro.2019.04.004","article-title":"Migraine in patients with fibromyalgia and outcomes of greater occipital nerve blockage","volume":"181","author":"Yilmaz","year":"2019","journal-title":"Clin Neurol Neurosurg"},{"key":"B41","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects","volume":"31","year":"2013","journal-title":"JAMA"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1111\/head.13617","article-title":"Onabotulinumtoxin-A in chronic migraine: should timing and definition of non-responder status be revised? suggestions from a real-life italian multicenter experience","volume":"59","author":"Vernieri","year":"2019","journal-title":"Headache"},{"key":"B43","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1177\/0333102418758283","article-title":"Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults","volume":"38","author":"Tassorelli","year":"2018","journal-title":"Cephalalgia"},{"key":"B44","doi-asserted-by":"publisher","first-page":"586","DOI":"10.3389\/fneur.2017.00586","article-title":"Long-term treatment benefits and prolonged efficacy of onabotulinumtoxinA in patients affected by chronic migraine and medication overuse headache over 3 years of therapy","volume":"8","author":"Guerzoni","year":"2017","journal-title":"Front Neurol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"808","DOI":"10.3389\/fneur.2018.00808","article-title":"OnabotulinumtoxinA: an effective tool in the therapeutic arsenal for chronic migraine with medication overuse","volume":"9","author":"Caronna","year":"2018","journal-title":"Front Neurol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1007\/s10072-016-2662-2","article-title":"Refractory chronic migraine: is drug withdrawal necessary before starting a therapy with onabotulinum toxin type A?","volume":"37","author":"Butera","year":"2016","journal-title":"Neurol Sci"},{"key":"B47","doi-asserted-by":"publisher","first-page":"140","DOI":"10.5152\/npa.2016.12691","article-title":"The impact of fibromyalgia on disability, anxiety, depression, sleep disturbance, and quality of life in patients with migraine","volume":"55","author":"Beyazal","year":"2018","journal-title":"Noro Psikiyatr Ars"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fneur.2020.575130\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T05:05:03Z","timestamp":1602738303000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fneur.2020.575130\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,15]]},"references-count":47,"alternative-id":["10.3389\/fneur.2020.575130"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2020.575130","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,15]]},"article-number":"575130"}}